Although targeting TGF-β signaling has a strong potential to treat cancers, hijacking crucial biological functions by antagonizing TGF-β signaling pathway carry the risk of disturbing the tumor suppressive homeostatic control of TGF-β in normal tissues and early cancers. The gene discussed is TGFB1; the disease is neoplasm.